Supervisory Board

Supervisory Board

 

XLS

 

 

 

 

Memberships of

Member

(a)
(b)

other statutory supervisory boards and
comparable German and foreign supervisory bodies of corporations

Prof. Dr. Dr. h. c. Rolf Krebs
Mainz, Retired physician, Chairman

(a)




(b)

– Epigenomics AG, Berlin (Chairman)
– Ganymed Pharmaceuticals AG, Mainz (Chairman)
– Merz GmbH & Co. KGaA, Frankfurt
– Senator GmbH & Co KGaA, Frankfurt
– Merz Pharmaceuticals GmbH, Frankfurt
– Board of Partners E. Merck KG, Darmstadt
– Air Liquide S.A., Paris

Heiner Wilhelm
Reinheim, Chairman of the Works Council of the Darmstadt site of Merck KGaA, Vice Chairman

no board positions

Crocifissa Attardo
Full-time member of the Works Council of the Darmstadt site of Merck KGaA

no board positions

Dr. Mechthild Auge
Wehrheim, Project manager for planning and information western Europe

no board positions

Johannes Baillou
Vienna, Austria, Entrepreneur

(b)

– Board of Partners E. Merck KG, Darmstadt (Vice Chairman)

Frank Binder
Zurich, Switzerland, Entrepreneur

(a)
(b)

– Landbell AG für Rückhol-Systeme, Mainz (Chairman)
– Board of Partners E. Merck KG, Darmstadt
– Board of Directors BMR-Yachting AG, Zurich (Chairman)
– Board of Directors Athena AG, Zurich

Dr. Wolfgang Büchele
Mannheim, Chief Executive Officer of BorsodChem Zrt, Hungary

(b)

– Board of Partners E. Merck KG, Darmstadt
– BorsodChem Zrt, Kazincbarcika, Hungary (Chairman of the Board)
– Kemira Oy, Helsinki, Finland
– First Chemical Holding Kft, Budapest, Hungary

Michael Fletterich
Gernsheim, Chairman of the Works Council of the Gernsheim site of Merck KGaA

no board positions

Edeltraud Glänzer
Wiesbaden, Member of the Managing Board of Industriegewerkschaft Bergbau, Chemie, Energie (IG BCE)

(a)

– B. Braun Melsungen AG, Melsungen
– Solvay Deutschland GmbH, Hannover (Vice Chairman)

Michaela Freifrau von Glenck
Zurich, Switzerland, Educator

no board positions

Frieder Kaufmann
Rossdorf, Full-time member of the Works Council of the Darmstadt site of Merck KGaA

no board positions

Dr. Hans-Jürgen Leuchs
Cobham, United Kingdom
Retired graduate chemist

(a)

(b)

– Zeton B.V., Enschede, The Netherlands
– Zeton International Inc., Burlington ONT, Canada (since Nov. 3, 2010)
– Board of Partners E. Merck KG, Darmstadt

Albrecht Merck
Schriesheim, Businessman

(b)

– Board of Partners E. Merck KG, Darmstadt

Dr. Karl-Heinz Scheider
Gross-Zimmern, Chemist

no board positions

Prof. Dr. Theo Siegert
Düsseldorf, Managing Partner of de Haen Carstanjen & Söhne, Düsseldorf

(a)



(b)

– Deutsche Bank AG, Frankfurt
– ERGO AG, Düsseldorf (until May 12, 2010)
– E.ON AG, Düsseldorf
– Henkel AG & Co KGaA, Düsseldorf
– Board of Partners E. Merck KG, Darmstadt
– Board of Directors DKSH Holding Ltd., Zurich, Switzerland

Osman Ulusoy
Wiesbaden, Regional Director of Industriegewerkschaft Bergbau, Chemie, Energie (IG BCE)

(a)

– Evonik Röhm GmbH, Darmstadt (Vice Chairman)

The Supervisory Board performs a monitoring function. It supervises the management of the company by the Executive Board. In comparison with the supervisory board of a German stock corporation, the role of the supervisory board of a corporation with general partners (KGaA) is limited. This is due to the fact that the members of the Executive Board are personally liable partners and therefore are responsible for the management of the company themselves. In particular, the Supervisory Board is not responsible for appointing and dismissing general partners or for regulating the terms and conditions of their contracts. The authority for this belongs to E. Merck KG. Nor does the Supervisory Board have the authority to issue rules of procedure for the Executive Board or a catalog of business transactions requiring approval. This authority likewise belongs to E. Merck KG (Art. 13 (3) sentence 1 and (4) sentence 1 of the Articles of Association). However, the fact that the Supervisory Board has no possibilities to directly influence the Executive Board restricts neither its information rights nor audit duties. The Supervisory Board must monitor the Executive Board in terms of legality, regularity, usefulness and economic efficiency. In particular, the Supervisory Board has the duty to examine the reports provided at least quarterly by the Executive Board about the progress of business – in particular sales and the position of the company. In addition, by means of consultation with the Executive Board, it creates the basis for supervision of the management of the company by the Supervisory Board according to section 111 (1) of the German Stock Corporation Act (AktG).

The Supervisory Board deals with the quarterly and half-year consolidated financial statements and examines the annual financial statements of the Merck Group as well as the annual financial statements of Merck KGaA, taking into account the auditor’s reports. The adoption of the annual financial statements is not the responsibility of the Supervisory Board, but of the General Meeting. The Supervisory Board normally meets four times a year. Further meetings may be convened if demanded by a member of either the Supervisory Board or the Executive Board. As a rule, resolutions of the Supervisory Board are passed at meetings. At the instruction of the chairman, in exceptional cases a resolution may be passed by other means, details of which are given in the rules of procedure.

The members of the Board of Partners of E. Merck KG and of the Supervisory Board may be convened to a joint meeting if so agreed by the chairmen of the two boards.

The rules of procedure prescribe that the Supervisory Board may form committees as and when necessary. The Supervisory Board currently has no committees. Because of the limited authority of the Supervisory Board, it does not appear appropriate to subdivide it further.